Aktis Oncology Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, that develops targeted radiopharmaceuticals for the treatment of solid tumors. The company utilizes a proprietary miniprotein radioconjugate platform designed to deliver alpha-emitting radioisotopes directly to cancer cells while limiting exposure to healthy tissue.